Premium
Darbepoetin‐alpha for the anaemia of myelofibrosis with myeloid metaplasia
Author(s) -
Cervantes Francisco,
AlvarezLarrán Alberto,
HernándezBoluda JuanCarlos,
Sureda Anna,
Granell Miquel,
Vallansot Rolando,
Besses Carles,
Montserrat Emili
Publication year - 2006
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2006.06142.x
Subject(s) - myelofibrosis , metaplasia , medicine , myeloid , alpha (finance) , extramedullary hematopoiesis , darbepoetin alfa , cancer research , haematopoiesis , anemia , biology , surgery , bone marrow , stem cell , construct validity , genetics , patient satisfaction
Summary Darbepoetin‐ α , a novel hyperglycosylated erythropoiesis‐stimulating protein, was administered to 20 patients with myelofibrosis with myeloid metaplasia and anaemia. The initial weekly dose, 150 μ g, was increased to 300 μ g when no response was observed after 4–8 weeks. Eight patients (40%) responded to treatment, including six complete and two partial responses, and five maintained their response at a median follow‐up of 12 months (range 4–22). Univariate analysis indicated that older age was the only factor associated with a favourable response to treatment ( P = 0.006). None of the patients with appropriate serum erythropoietin levels responded. Treatment was usually well tolerated.